多中心分析:经会阴影像融合靶向与非靶向系统前列腺穿刺活检在高危男性中检出临床显著性前列腺癌的比较
该多中心研究纳入英国11个中心640例PSA升高的男性,行经会阴影像融合靶向穿刺(部分联合非靶向穿刺)。靶向穿刺单独检出临床显著性前列腺癌(csPC)41.1%,非靶向穿刺仅0.8%的病例独有csPC,但非靶向穿刺检出临床 insignificant 癌达26.1%。结论认为仅靶向穿刺方案对csPC检出率高且 insignificant 癌检出率低。
要点
- 靶向穿刺单独检出csPC 263/640例(41.1%),非靶向穿刺仅3/357例(0.8%)独有csPC。
- 非靶向穿刺检出临床 insignificant 癌93/357例(26.1%)。
- 局限性包括并非所有男性均接受非靶向穿刺。
核心结论
- 在该大型多中心系列中,非靶向前列腺穿刺针芯的csPC检出率低,而临床 insignificant 前列腺癌检出率高。
- 仅行影像融合靶向穿刺的方案维持对csPC的高检出和对临床 insignificant 癌的低检出。
研究设计与样本
- 研究纳入英国11个中心13名泌尿外科医生诊治的640例连续PSA升高患者,于2014年4月至2017年6月期间接受首次穿刺或既往经直肠穿刺阴性后穿刺。
- 在多参数MRI后行经会阴穿刺:仅靶向穿刺组283例,靶向联合非靶向穿刺组357例,采用经会阴刚性影像融合靶向穿刺(MIM-Symphony-DX)。
- 临床显著性主要定义:Gleason≥4+3或任何分级≥6mm。
主要发现
- 队列平均年龄63.8岁(SD 8.4),中位PSA 6.3 ng/ml(SD 5.8),中位前列腺体积42.0 cm3(SD 24.7)。
- 总体276/640例(43.1%)诊断为csPC。
- 仅靶向穿刺检出csPC 263/640例(41.1%)。
- 357例接受非靶向穿刺者中,3例(0.8%)仅非靶向针芯有csPC且靶向针芯无癌证据。
- 357例接受非靶向穿刺者中,无论靶向穿刺结果如何,32例(9.0%)在非靶向穿刺中检出csPC;非靶向穿刺检出临床 insignificant 病93/357例(26.1%)。
关键数值与推荐
- 主要临床显著性定义:Gleason≥4+3或任何分级≥6mm。
- 其他临床显著性阈值下结果一致。
临床怎么用
- 原文结论认为,在前列腺多参数MRI及可疑区域经会阴靶向穿刺后,额外对非可疑区域行广泛非导向穿刺的临床价值有限,且常发现无需治疗的 insignificant 癌。
局限性
- 局限性包括并非所有男性均接受了非靶向穿刺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate biopsy guided by magnetic resonance imaging (MRI) is increasingly used to obtain tissue from men with suspected prostate cancer (PC). OBJECTIVE: To report a multicentre series of image-fusion transperineal prostate biopsies and compare the diagnostic yield of clinically significant PC (csPC) between targeted and nontargeted biopsies. DESIGN, SETTING, AND PARTICIPANTS: The study included 640 consecutive patients with elevated prostate specific antigen (PSA) presenting for first biopsy or following a previous negative transrectal biopsy under the care of 13 urologists in 11 centres in the UK (April 2014-June 2017). INTERVENTION: Multiparametric MRI was carried out in 61 approved prostate MRI centres with transperineal targeted alone (n=283) or targeted plus nontargeted (n=357) transperineal rigid image-fusion targeted biopsy (MIM-Symphony-DX). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Rates of csPC and insignificant cancer detection in targeted and nontargeted biopsies were measured using a number of thresholds to define clinical significance. The primary definition was Gleason≥4+3 or any grade ≥6mm. RESULTS AND LIMITATIONS: The mean age, median PSA, and median prostate volume for the cohort were 63.8yr (standard deviation [SD] 8.4), 6.3 ng/ml (SD 5.8), and 42.0cm3 (SD 24.7), respectively. Overall, 276/640 men (43.1%) were diagnosed with csPC. csPC was detected from targeted biopsies alone in 263/640 cases (41.1%). Of the 357 men who underwent nontargeted biopsies, three (0.8%) had csPC exclusively in nontargeted cores, with no evidence of cancer in targeted cores. Overall, 32/357 (9.0%) had csPC in nontargeted biopsies regardless of the targeted biopsy findings. Clinically insignificant disease in nontargeted biopsies was detected in 93/357 men (26.1%). Our findings were consistent across all other thresholds of clinical significance. Limitations include the lack of nontargeted biopsies in all men. CONCLUSIONS: In this large multicentre series, nontargeted prostate biopsy cores had a low yield of csPC and a high yield of clinically insignificant PC. An image-fusion targeted-biopsy-only approach maintains high detection for csPC and low detection of clinically insignificant cancers. PATIENT SUMMARY: In this report, we found that following prostate multiparametric magnetic resonance imaging and targeted transperineal biopsies of suspicious areas, the clinical value of performing additional extensive unguided biopsies of nonsuspicious areas is limited and can often find insignificant cancers that do not need treatment.
引用
- Miah S, Hosking-Jervis F, Connor MJ, et al. A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. Eur Urol Oncol. 2019. PMID: 31411968. doi:10.1016/j.euo.2019.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。